

Sientra, Inc.  
Form 8-K  
January 08, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): January 7, 2016**

**SIENTRA, INC.**

**(Exact Name of Registrant as Specified in Its Charter)**

**Delaware**  
**(State or Other Jurisdiction**  
**of Incorporation)**

**001-36709**  
**(Commission**  
**File Number)**

**20-5551000**  
**(IRS Employer**  
**Identification No.)**

Edgar Filing: Sientra, Inc. - Form 8-K

**420 South Fairview Avenue, Suite 200**

**Santa Barbara, CA 93117**

**(Address of Principal Executive Offices and Zip Code)**

**(805) 562-3500**

**(Registrant's Telephone Number, Including Area Code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On January 7, 2016, Sientra, Inc. (the *Company* or *Sientra*) sent a letter to surgeons regarding the independent third-party testing of Sientra's products, the submission of such test results to the FDA and other business updates. A copy of the letter is filed as Exhibit 99.1 and is incorporated herein by reference.

***Forward-Looking Statements***

Certain statements incorporated by reference into this Current Report on Form 8-K are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, relating to, among other things, the future performance of Sientra that are based on management's current assumptions and expectations of future events and involve risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding: the results of the independent third-party testing of Sientra's products; Sientra's current inventory supply; and the actions that the FDA may take in response to the results of the independent third-party testing of Sientra's products. Such statements are subject to risks and uncertainties. The Company's business, strategy, operations or financial performance, and actual results may differ materially from those predicted or implied. All statements other than statements of historical fact are forward-looking statements. The words believe, will, continue, expect, plan, or the negative or similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. More information about factors that could cause actual results to differ materially from those incorporated by reference into this Current Report on Form 8-K can be found under the captions Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's most recent Quarterly Report on Form 10-Q at <http://investors.sientra.com/financial-info/sec-filings/default.aspx> or the SEC's website at [www.sec.gov](http://www.sec.gov). Undue reliance should not be placed on the forward-looking statements incorporated by reference herein, which are based on information available to the Company on the date hereof, and except to the extent required by law, Sientra assumes no obligation to update such statements.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

Exhibit No.	Description
99.1	Letter of Sientra, Inc. dated January 7, 2016.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereto duly authorized.

**SIENTRA, INC.**

Dated: January 7, 2016

By: */s/ Jeffrey Nugent*  
Jeffrey Nugent  
*Chief Executive Officer*

---

**INDEX TO EXHIBITS**

Exhibit No.	Description
99.1	Letter of Sientra, Inc. dated January 7, 2016.

---